Exelixis (EXEL) Long-Term Investments (2010 - 2026)
Exelixis' (EXEL) quarterly Long-Term Investments came in at $649.1 million in Q2 2026, up 4.8% year-on-year from $619.4 million in Q2 2025, and up 7.54% quarter-over-quarter from $603.6 million in Q1 2026.
Exelixis (EXEL) Long-Term Investments (2010 - 2026) Analysis & Trends
Exelixis' Long-Term Investments history runs 17 years deep, the most recent figure standing at $649.1 million for Q2 2026.
- On a quarterly basis, Long-Term Investments rose 4.8% year-over-year to $649.1 million in Q2 2026; TTM through Apr 2026 was $649.1 million, a 4.8% increase from a year earlier, with the FY2026 full-year figure at $603.6 million, down 5.29% from the prior year.
- Long-Term Investments rose to $649.1 million in Q2 2026 per EXEL's latest filing, from $603.6 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $838.6 million in Q2 2023 and bottomed at $404.5 million in Q2 2022.
- The 5-year median for Long-Term Investments is $619.4 million (2025), against an average of $625.3 million.
- Across the five-year window, Long-Term Investments soared 103.91% in 2022 and plunged 48.45% in 2024, its largest moves.
- Year by year, Long-Term Investments stood at $756.7 million in 2022, then slipped by 3.7% to $728.7 million in 2023, then dropped by 28.17% to $523.4 million in 2024, then increased by 10.48% to $578.3 million in 2025, then climbed by 12.25% to $649.1 million in 2026.
- Per Business Quant, the three latest EXEL Long-Term Investments figures stand at $649.1 million (Q2 2026), $603.6 million (Q1 2026), and $578.3 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 649.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 649.14 Mn |
| Jan 2, 2026 | 603.60 Mn |
| Oct 3, 2025 | 578.29 Mn |
| Jul 4, 2025 | 594.65 Mn |
| Apr 4, 2025 | 619.44 Mn |
| Jan 3, 2025 | 637.29 Mn |
| Sep 27, 2024 | 523.42 Mn |
| Jun 28, 2024 | 432.31 Mn |
| Mar 29, 2024 | 629.56 Mn |
| Dec 29, 2023 | 728.72 Mn |
| Sep 29, 2023 | 811.68 Mn |
| Jun 30, 2023 | 838.62 Mn |
| Mar 31, 2023 | 806.62 Mn |
| Dec 30, 2022 | 756.73 Mn |
| Sep 30, 2022 | 551.74 Mn |
| Jul 1, 2022 | 463.89 Mn |
| Apr 1, 2022 | 404.54 Mn |
| Dec 31, 2021 | 371.11 Mn |
| Oct 1, 2021 | 362.22 Mn |
| Jul 2, 2021 | 345.61 Mn |